Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis

V. Rodriguez-Cerrato, C. C. McCoig, I. C. Michelow, F. Ghaffar, H. S. Jafri, R. D. Hardy, C. Patel, K. Olsen, Jr McCracken G.H.

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (Cmax) values were 1.8, 4.2, and 4.9 μg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 μg/ml · h, respectively, and the half-life values (t1/2) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Δlog10 CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were -5.70, -6.62, and -7.02; -7.37, -7.37, and -6.87; and -6.62, -6.62, and -6.62, respectively, whereas those of ceftriaxone and meropenem were -4.18, -5.24, and -4.43, and -3.64, -3.59, and -4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and Cmax/MBC were interrelated (r = 0.81); there was less correlation with T > MBC (r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF.

Original languageEnglish (US)
Pages (from-to)3092-3097
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume45
Issue number11
DOIs
StatePublished - 2001

Fingerprint

Escherichia coli Meningitis
meropenem
Cerebrospinal Fluid
Ceftriaxone
moxifloxacin
Meningitis
Half-Life
Therapeutics
Escherichia coli
Rabbits

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. / Rodriguez-Cerrato, V.; McCoig, C. C.; Michelow, I. C.; Ghaffar, F.; Jafri, H. S.; Hardy, R. D.; Patel, C.; Olsen, K.; McCracken G.H., Jr.

In: Antimicrobial Agents and Chemotherapy, Vol. 45, No. 11, 2001, p. 3092-3097.

Research output: Contribution to journalArticle

Rodriguez-Cerrato, V, McCoig, CC, Michelow, IC, Ghaffar, F, Jafri, HS, Hardy, RD, Patel, C, Olsen, K & McCracken G.H., J 2001, 'Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis', Antimicrobial Agents and Chemotherapy, vol. 45, no. 11, pp. 3092-3097. https://doi.org/10.1128/AAC.45.11.3092-3097.2001
Rodriguez-Cerrato, V. ; McCoig, C. C. ; Michelow, I. C. ; Ghaffar, F. ; Jafri, H. S. ; Hardy, R. D. ; Patel, C. ; Olsen, K. ; McCracken G.H., Jr. / Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. In: Antimicrobial Agents and Chemotherapy. 2001 ; Vol. 45, No. 11. pp. 3092-3097.
@article{55d025fa2a564c339d7c4217db4222a3,
title = "Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis",
abstract = "Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50{\%}. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (Cmax) values were 1.8, 4.2, and 4.9 μg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 μg/ml · h, respectively, and the half-life values (t1/2) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Δlog10 CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were -5.70, -6.62, and -7.02; -7.37, -7.37, and -6.87; and -6.62, -6.62, and -6.62, respectively, whereas those of ceftriaxone and meropenem were -4.18, -5.24, and -4.43, and -3.64, -3.59, and -4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and Cmax/MBC were interrelated (r = 0.81); there was less correlation with T > MBC (r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF.",
author = "V. Rodriguez-Cerrato and McCoig, {C. C.} and Michelow, {I. C.} and F. Ghaffar and Jafri, {H. S.} and Hardy, {R. D.} and C. Patel and K. Olsen and {McCracken G.H.}, Jr",
year = "2001",
doi = "10.1128/AAC.45.11.3092-3097.2001",
language = "English (US)",
volume = "45",
pages = "3092--3097",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis

AU - Rodriguez-Cerrato, V.

AU - McCoig, C. C.

AU - Michelow, I. C.

AU - Ghaffar, F.

AU - Jafri, H. S.

AU - Hardy, R. D.

AU - Patel, C.

AU - Olsen, K.

AU - McCracken G.H., Jr

PY - 2001

Y1 - 2001

N2 - Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (Cmax) values were 1.8, 4.2, and 4.9 μg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 μg/ml · h, respectively, and the half-life values (t1/2) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Δlog10 CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were -5.70, -6.62, and -7.02; -7.37, -7.37, and -6.87; and -6.62, -6.62, and -6.62, respectively, whereas those of ceftriaxone and meropenem were -4.18, -5.24, and -4.43, and -3.64, -3.59, and -4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and Cmax/MBC were interrelated (r = 0.81); there was less correlation with T > MBC (r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF.

AB - Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (Cmax) values were 1.8, 4.2, and 4.9 μg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 μg/ml · h, respectively, and the half-life values (t1/2) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Δlog10 CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were -5.70, -6.62, and -7.02; -7.37, -7.37, and -6.87; and -6.62, -6.62, and -6.62, respectively, whereas those of ceftriaxone and meropenem were -4.18, -5.24, and -4.43, and -3.64, -3.59, and -4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and Cmax/MBC were interrelated (r = 0.81); there was less correlation with T > MBC (r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF.

UR - http://www.scopus.com/inward/record.url?scp=0034769961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034769961&partnerID=8YFLogxK

U2 - 10.1128/AAC.45.11.3092-3097.2001

DO - 10.1128/AAC.45.11.3092-3097.2001

M3 - Article

C2 - 11600361

AN - SCOPUS:0034769961

VL - 45

SP - 3092

EP - 3097

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -